Induction therapy with a novel interleukin 6 (IL-6) inhibitor for active ulcerative colitis yielded significantly higher rates of clinical response, remission, and mucosal healing than placebo, ...

Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its decision to spin out its own candidate into a separate company. In September, Tiziana ...

An update from Bluejay Diagnostics ( ($BJDX) ) is now available. On December 29, 2025, Bluejay Diagnostics announced it had completed ...

Besides being an immune protein, IL-6 is also a pyrogen and is responsible for fever in autoimmune, infectious, or non-infectious diseases. IL-6 is produced in the body, wherever there is inflammation ...

Interleukin-6 (IL-6) is a pleiotropic cytokine secreted by T cells and macrophages to activate immune responses during infection or after trauma. IL-6 plays an important role in a number of bodily ...

However, imbalances of IL-6 — too much or too little — can cause disease, even in the absence of infection. Excess IL-6 is central to the pathogenesis of inflammatory reactions like rheumatoid disease ...

Your doctor has recommended expanding your treatment plan for rheumatoid arthritis (RA) to include an interleukin 6 (IL-6) inhibitor — a biologic that’s often prescribed when conventional ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. WASHINGTON — Patients with inflammatory arthritis who ...

Bluejay Diagnostics, Inc. (NASDAQ: BJDX) ('Bluejay” or the 'Company”) announced that it has completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 ...

Vaccine immunotherapy targeting interleukin 6 (IL-6) has shown promising results in the treatment of inflammatory osteoarthritis of the knee, according to a phase 1 double-blind controlled study.